Alector is a clinical stage biopharmaceutical company developing immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. AL001, Co.'s initial product candidate, modulates progranulin (PRGN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. AL101, Co.'s second product candidate in its PGRN portfolio, is designed to treat people suffering from more prevalent neurodegenerative diseases. AL003 is another product candidate designed to treat patients with Alzheimer's disease. Co.'s development program, AL044, is developing Co.'s product candidate that targets MS4A4A, a main risk gene for Alzheimer's disease. The ALEC stock yearly return is shown above.
The yearly return on the ALEC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ALEC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|